Literature DB >> 28487256

Lipopolysaccharide (LPS) induced pulmonary neutrophil recruitment and platelet activation is mediated via the P2Y1 and P2Y14 receptors in mice.

R T Amison1, S Arnold1, B G O'Shaughnessy1, S J Cleary1, J Ofoedu1, M Idzko2, C P Page1, S C Pitchford3.   

Abstract

Platelet activation occurs during host defence and in various inflammatory disorders. In animal models of infection and inflammation, experimental depletion of platelets leads to significantly reduced leukocyte recruitment and impaired clearance of pathogens from the lung. It is now appreciated that purinergic receptor activation is required for leukocyte activation, motility and adhesion, and platelet interactions with leukocytes can be modulated by purinergic stimulation of platelets. Here, we have investigated the role of platelet P2Y1, P2Y12, P2Y14, and P2X1 receptors on leukocyte recruitment and chemotaxis. Mice were administered either vehicle controls or selective P2Y1, P2Y12, P2Y14, or P2X1 antagonists intravenously before intranasal administration of lipopolysaccharide (LPS) to investigate the effect of these drugs on pulmonary leukocyte recruitment, peripheral platelet counts, bleeding times, and ex vivo platelet aggregation. Separately, platelets were incubated with P2Y1, P2Y12, P2X1 antagonists, or P2Y14 agonists to assess effects on platelet-induced neutrophil chemotaxis in vitro. Pulmonary neutrophil recruitment induced by intranasal LPS administration was inhibited in mice administered either with P2Y1 or P2Y14 antagonists, but not with P2Y12 or P2X1 antagonists. Furthermore, the administration of either a P2Y1 or a P2Y14 antagonist reversed the incidence of peripheral thrombocytopaenia associated with LPS exposure. Bleeding times were significantly increased in mice administered P2Y1, P2Y12, or P2X1 antagonists, whilst ex vivo platelet aggregation to ADP was significantly reduced. These haemostatic responses remained unaltered following antagonism of P2Y14. In vitro chemotaxis assays revealed direct antagonism of platelet P2Y1, but not P2Y12 or P2X1 receptors suppressed platelet-dependent neutrophil motility towards Macrophage derived chemokine (MDC, CCL22). Furthermore, the stimulation of platelets with selective P2Y14 agonists (UDP-glucose, MRS2690) resulted in significant platelet-dependent neutrophil chemotaxis. These results reveal a role for P2Y1 and P2Y14 activation of platelets following exposure to LPS, whilst haemostatic indices were unaffected by inhibition of platelet function with the P2Y14 antagonist in response to LPS.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28487256     DOI: 10.1016/j.pupt.2017.05.005

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  14 in total

1.  LPS-induced Lung Platelet Recruitment Occurs Independently from Neutrophils, PSGL-1, and P-Selectin.

Authors:  Simon J Cleary; Carl Hobbs; Richard T Amison; Stephanie Arnold; Blaze G O'Shaughnessy; Emma Lefrançais; Beñat Mallavia; Mark R Looney; Clive P Page; Simon C Pitchford
Journal:  Am J Respir Cell Mol Biol       Date:  2019-08       Impact factor: 6.914

Review 2.  Amicus or Adversary Revisited: Platelets in Acute Lung Injury and Acute Respiratory Distress Syndrome.

Authors:  Elizabeth A Middleton; Matthew T Rondina; Hansjorg Schwertz; Guy A Zimmerman
Journal:  Am J Respir Cell Mol Biol       Date:  2018-07       Impact factor: 6.914

3.  Structure-Guided Modification of Heterocyclic Antagonists of the P2Y14 Receptor.

Authors:  Jinha Yu; Antonella Ciancetta; Steven Dudas; Sierra Duca; Justine Lottermoser; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2018-05-16       Impact factor: 7.446

4.  Pulmonary Inflammation and KRAS Mutation in Lung Cancer.

Authors:  Phouthone Keohavong; Y Peter Di
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Platelet-Eosinophil Interactions As a Potential Therapeutic Target in Allergic Inflammation and Asthma.

Authors:  Sajeel A Shah; Clive P Page; Simon C Pitchford
Journal:  Front Med (Lausanne)       Date:  2017-08-08

6.  Effects of bacterial lipopolysaccharides on platelet function: inhibition of weak platelet activation.

Authors:  Alexey A Martyanov; Aleksandr S Maiorov; Aleksandra A Filkova; Alexander A Ryabykh; Galina S Svidelskaya; Elena O Artemenko; Stepan P Gambaryan; Mikhail A Panteleev; Anastasia N Sveshnikova
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.379

Review 7.  Purinergic Regulation of Neutrophil Function.

Authors:  Xu Wang; Deyu Chen
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

Review 8.  Eosinophils and Purinergic Signaling in Health and Disease.

Authors:  Davide Ferrari; Marta Vuerich; Fabio Casciano; Maria Serena Longhi; Elisabetta Melloni; Paola Secchiero; Andreas Zech; Simon C Robson; Tobias Müller; Marco Idzko
Journal:  Front Immunol       Date:  2020-07-08       Impact factor: 7.561

9.  Prevention of P2 Receptor-Dependent Thrombocyte Activation by Pore-Forming Bacterial Toxins Improves Outcome in A Murine Model of Urosepsis.

Authors:  Mette G Christensen; Nanna Johnsen; Marianne Skals; Aimi D M Hamilton; Peter Rubak; Anne-Mette Hvas; Helle Praetorius
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

10.  Cangrelor ameliorates CLP-induced pulmonary injury in sepsis by inhibiting GPR17.

Authors:  Qiancheng Luo; Rui Liu; Kaili Qu; Guorong Liu; Min Hang; Guo Chen; Lei Xu; Qinqin Jin; Dongfeng Guo; Qi Kang
Journal:  Eur J Med Res       Date:  2021-07-06       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.